{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He Z"],"funding":["Medico- Engineering   Cooperation  Funds from  University  of  Electronic  Science and  Technology  of China","Medico- Engineering Cooperation Funds from University of Electronic Science and Technology of China","Foundation for Sichuan Provincial People’s Hospital","Foundation for Sichuan Provincial People's Hospital"],"pagination":["443"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9526964"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["<h4>Background</h4>Gliomas account for about 80% of all malignant brain and other central nervous system (CNS) tumors. Temozolomide (TMZ) resistance represents a major treatment hurdle. Adrenomedullin (ADM) has been reported to induce glioblastoma cell growth.<h4>Methods</h4>Cell viability was measured using the CCK-8 assay. The apoptosis analysis was performed using the Annexin V-FITC Apoptosis Detection Kit. The mitochondrial membrane potential was determined by JC-1 staining. A nude mouse tumor assay was used to detect tumor formation. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were performed in tissue sections. Activation of Akt and Erk and expression of apoptosis-related proteins were determined by immunoblotting.<h4>Results</h4>ADM expression has been found up"],"journal":["Journal of translational medicine"],"pubmed_title":["miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)."],"pmcid":["PMC9526964"],"funding_grant_id":["2021LY03","ZYGX2021YGLH209"],"pubmed_authors":["Tang J","Liu L","He Z","Hu J","Chen L","Liu P","Cao D","Cheng M"],"additional_accession":[]},"is_claimable":false,"name":"miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).","description":"<h4>Background</h4>Gliomas account for about 80% of all malignant brain and other central nervous system (CNS) tumors. Temozolomide (TMZ) resistance represents a major treatment hurdle. Adrenomedullin (ADM) has been reported to induce glioblastoma cell growth.<h4>Methods</h4>Cell viability was measured using the CCK-8 assay. The apoptosis analysis was performed using the Annexin V-FITC Apoptosis Detection Kit. The mitochondrial membrane potential was determined by JC-1 staining. A nude mouse tumor assay was used to detect tumor formation. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were performed in tissue sections. Activation of Akt and Erk and expression of apoptosis-related proteins were determined by immunoblotting.<h4>Results</h4>ADM expression has been found up","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2025-04-19T11:32:37.824Z","creation":"2025-04-19T11:32:37.824Z"},"accession":"S-EPMC9526964","cross_references":{"pubmed":["36183123"],"doi":["10.1186/s12967-022-03647-6"]}}